DEV Community: Lucasbromley

Fertility Treatment Market Size, Share, Growth, and Forecast 2032 : BAMG Consulting

Lucasbromley — Mon, 20 Jul 2026 06:00:57 +0000

BMAG CONSULTING UNVEILS REPORT FORECASTING ROBUST GROWTH IN GLOBAL FERTILITY TREATMENT MARKET, DRIVEN BY INNOVATION AND EVOLVING DEMOGRAPHICS
FLORIDA, United States, July 5, 2026 — FOR IMMEDIATE RELEASE
BMAG Consulting, a premier global advisory firm, today announced the release of its comprehensive report on the Global Fertility Treatment Market. The groundbreaking analysis projects significant expansion in the sector, driven by advancements in assisted reproductive technologies (ART), increasing awareness, and a rising global incidence of infertility. The report provides critical insights into market dynamics, strategic opportunities, and challenges shaping the future of reproductive healthcare, positioning stakeholders for informed decision-making in a rapidly evolving landscape.

The newly published report details that the global fertility treatment market is poised for substantial Compound Annual Growth Rate (CAGR) over the next decade, with key drivers including delayed parenthood, lifestyle changes, and enhanced access to fertility services. Innovations in IVF techniques, genetic testing, and fertility preservation are identified as central to this growth, offering more personalized and effective treatment options for individuals and couples worldwide.

Download Free Sample Report: https://bmagconsulting.com/sample/fertility-treatment-market

BMAG Consulting’s analysis delves into the geographical nuances of the market, highlighting emerging economies as new frontiers for growth due to improving healthcare infrastructure and increasing disposable incomes. Concurrently, established markets in North America and Europe continue to innovate, focusing on patient-centric care models and integrating digital health solutions. The report emphasizes the importance of understanding regional regulatory frameworks and cultural sensitivities for successful market penetration.
The study also sheds light on the competitive landscape, profiling leading players and analyzing their strategic initiatives, including mergers, acquisitions, and collaborations. It provides a forward-looking perspective on how technological disruptions, such as AI-driven diagnostics and gene editing, could redefine treatment paradigms, urging market participants to foster agility and embrace innovation to maintain a competitive edge.

THE REGULATORY PIVOT
The regulatory landscape for fertility treatments is undergoing a significant transformation, moving beyond a 'one-size-fits-all' approach to embrace more nuanced, patient-specific guidelines. This shift is driven by the rapid evolution of diagnostic tools and treatment modalities, necessitating bespoke regulatory frameworks that ensure both safety and efficacy without stifling innovation. Key trends include: increased scrutiny on genetic screening technologies, harmonization of ART guidelines across regions to facilitate cross-border treatment, and the ethical integration of AI into diagnostic processes. Companies must navigate these complex, often divergent, regulatory pathways to ensure market access and compliance, requiring robust clinical validation and transparent ethical practices.

STRATEGIC MARKET OUTLOOK
The Strategic Market Outlook for the fertility treatment sector is characterized by several powerful demand engines. Rising global infertility rates stemming from lifestyle factors, environmental influences, and delayed childbearing are creating an undeniable imperative for effective solutions. Advancements in cryopreservation techniques and preimplantation genetic testing (PGT) are expanding treatment accessibility and success rates. Furthermore, the growing acceptance and normalization of fertility treatments, coupled with increasing healthcare expenditure in emerging markets, are fueling demand. The report also highlights the rising trend of fertility preservation for cancer patients and LGBTQ+ individuals as significant niche but growing segments driving future market expansion.

View Full Advisory Report: https://bmagconsulting.com/report/fertility-treatment-market

ABOUT BMAG CONSULTING
BMAG Consulting is a boutique advisory firm renowned for delivering precision execution and transformative strategies to global clients across diverse industries. Our expertise lies in distilling complex market dynamics into actionable intelligence, enabling our partners to navigate competitive landscapes, optimize operations, and achieve sustainable growth. With a commitment to innovation and deep industry insights, BMAG Consulting empowers organizations to make informed decisions and realize their full potential.

MEDIA CONTACT
Contact: Mary Joseph, Senior Consultant
Organization: BMAG Consulting
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

Oligonucleotide Therapeutics Market Size, Share, Growth, and Forecast 2031 : BAMG Consulting

Lucasbromley — Wed, 15 Jul 2026 11:16:17 +0000

BMAG CONSULTING UNVEILS LANDMARK REPORT FORECASTING EXPONENTIAL GROWTH IN GLOBAL OLIGONUCLEOTIDE THERAPEUTICS MARKET

FLORIDA, United States, July 5, 2026 — FOR IMMEDIATE RELEASE
BMAG Consulting, a leading global advisory firm, today announced the release of its comprehensive new report: "The Global Oligonucleotide Therapeutics Market: Growth Drivers, Regulatory Landscape, and Competitive Strategies 2026-2035*." The report projects a robust compound annual growth rate (CAGR) of over 15%, driven by groundbreaking advancements in genetic medicine and increasing investment in novel drug discovery. This pivotal analysis offers unparalleled insights into a market poised to redefine treatment paradigms for a myriad of diseases, from rare genetic disorders to widespread chronic conditions.

The burgeoning oligonucleotide therapeutics sector is experiencing unprecedented innovation, fueled by breakthroughs in mRNA, siRNA, antisense oligonucleotides (ASOs), and aptamers. BMAG Consulting's report highlights how these modalities are rapidly transitioning from research concepts to approved therapies, offering high specificity and reduced off-target effects compared to traditional small molecule drugs. Key market drivers include the rising prevalence of genetic and chronic diseases, strategic collaborations between biopharmaceutical giants and biotech startups, and a burgeoning pipeline of therapeutic candidates targeting previously intractable conditions.
Download Free Sample Report: https://bmagconsulting.com/sample/oligonucleotide-therapeutics-market
Furthermore, the study delves into the critical factors influencing market penetration, such as advancements in drug delivery systems and formulation technologies which are crucial for enhancing therapeutic efficacy and patient compliance. The report also scrutinizes the competitive landscape, profiling key players, their strategic initiatives, and investment trends that are shaping the future of this dynamic market. Stakeholders will gain a clear understanding of regional market dynamics, emerging opportunities, and potential challenges to inform their strategic decision-making.

THE REGULATORY PIVOT
The regulatory landscape for oligonucleotide therapeutics is undergoing a significant transformation, moving beyond 'one-size-fits-all' diagnostics towards more adaptive and expedited pathways. Regulatory bodies globally are recognizing the unique characteristics and potential of these therapies, leading to more tailored review processes. Our analysis reveals a trend towards: 1. Fast-track designations for therapies addressing unmet medical needs. 2. Increased collaboration between regulators and developers to streamline clinical trials. 3. Development of specific guidelines for gene-editing and RNA-based therapeutics, acknowledging their novel mechanisms. This pivot is critical for accelerating market access and ensuring patient safety while fostering innovation.

STRATEGIC MARKET OUTLOOK
The strategic market outlook for oligonucleotide therapeutics is highly optimistic, propelled by several robust demand engines: 1. Expanding Therapeutic Indications: Beyond rare diseases, applications are broadening into oncology, cardiovascular diseases, and neurology. 2. Advancements in Delivery Systems: Novel nanoparticle formulations and targeted delivery methods are enhancing bioavailability and reducing toxicity. 3. Increased R&D Investment: Significant capital infusion from venture capitalists and pharmaceutical companies is fueling preclinical and clinical development. 4. Personalized Medicine Integration: Oligonucleotide therapies are perfectly positioned for precision medicine, offering highly customized treatments. These engines collectively signify a future of sustained growth and transformative impact across healthcare sectors.

View Full Advisory Report: https://bmagconsulting.com/report/oligonucleotide-therapeutics-market

ABOUT BMAG CONSULTING
BMAG Consulting is a premier global advisory firm specializing in providing bespoke market intelligence and strategic guidance to enterprises navigating complex industry landscapes. Renowned for its boutique advisory services and commitment to precision execution, BMAG Consulting empowers clients worldwide to achieve sustainable growth and market leadership through actionable insights and data-driven strategies.

MEDIA CONTACT
Contact: Mary Joseph, Senior Consultant
Organization: BMAG Consulting
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

Biopharmaceutical Manufacturing Market Size, Share, Growth, and Forecast 2031 : BAMG Consulting

Lucasbromley — Mon, 13 Jul 2026 10:21:09 +0000

GLOBAL BIOPHARMACEUTICAL MANUFACTURING MARKET POISED FOR SUBSTANTIAL GROWTH THROUGH 2035, DRIVEN BY INNOVATION AND DIGITAL TRANSFORMATION
FLORIDA, United States, July 5, 2026 — FOR IMMEDIATE RELEASE
BMAG Consulting, a premier global advisory firm, today announced the release of its groundbreaking report, "The Global Biopharmaceutical Manufacturing Market: Strategic Outlook 2026-2035." The comprehensive analysis projects the market to reach USD 1.55 Trillion by 2035, exhibiting a robust CAGR of 10.5%, propelled by escalating demand for advanced biologics, gene therapies, and precision medicines. This pivotal research offers critical insights into the evolving landscape, highlighting the strategic shifts necessary for stakeholders to capitalize on unprecedented opportunities.
The report Separates carefully key growth drivers, including the rapid expansion of the biologics pipeline, Major developments in cell and gene therapies, And the increasing adoption of Disposable technologies and continuous manufacturing processes. It emphasizes how these innovations are not just adding. Production efficiency But also tackle elaborate challenges drug development and delivery, Finally, phase to market is accelerating life- saving therapeutics.
Download Free Sample Report: https://bmagconsulting.com/sample/biopharmaceutical-manufacturing-market
In addition, BMAG Consulting's analysis Identifies critical operational hurdles Esteem supply chain vulnerabilities, Lack of qualified labour, and the need for it sustainable manufacturing practices.The report gives actionable strategies To overcome these challenges, Advocate for robust digital integration, Strategic outsourcing partnerships, and investments in next- generation bioprocessing technologies to ensure flexibility and agility manufacturing ecosystems capable Of meeting future demand.
THE REGULATORY PIVOT
The Regulatory Pivot: Going beyond' one- size- fits- all', interest in assessment. The seismic shifts I regulatory frameworks, Especially as the industry Moving towards personalization and precision medicine. * Traditional regulatory pathways prove to be insufficient. The rapid pace of innovation I advanced therapies.The report highlights the growing need for adaptive regulatory frameworks which can be adjusted novel modalities, Speed up approvals for unmet medical needs, And make sure product quality And patient safety Without innovation. It highlights. The trend Goes beyond general diagnostics and production monitoring to a more nuanced, risk- based approach, towards area- specific and indication- specific guidelines approach crucial to future market success.
STRATEGIC MARKET OUTLOOK
Strategic Market Outlook: demand Engines Consideration the core drivers It will fuel the biopharmaceutical manufacturing market's growth over the next decade. These include:* Booming Biologics Pipeline*: Increase in monoclonal antibodies, therapeutic proteins, and vaccines. * Advanced Therapy Medicinal Products( ATMPs): Significant investment And clinical success in cell and gene therapies. Agreement Development and Manufacturing Organizations( CDMOs): Increase confidence in CDMOs to specialized expertise, capacity expansion, and cost efficiencies. * Digital Transformation& Automation*: Adaptation to the industry 4.0 technologies, AI, and machine Learn for better productivity, quality control, and supply chain management. * Emerging Markets*: Increasing demand and production capacity. APAC And other developing regions.
View Full Advisory Report: https://bmagconsulting.com/report/biopharmaceutical-manufacturing-market

ABOUT BMAG CONSULTING
BMAG Consulting is a boutique advisory firm renowned for delivering bespoke strategic solutions to global leaders across diverse industries. With a strong emphasis on data-driven insights and precision execution, BMAG empowers clients to navigate complex market dynamics, capitalize on emerging opportunities, and achieve sustainable competitive advantage. Our expert teams are committed to fostering innovation, optimizing operational excellence, and driving measurable, long-term success for our distinguished clientele worldwide.
MEDIA CONTACT
Contact: Mary Joseph, Senior Consultant
BMAG Consulting

Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

Companion Diagnostics Market Size, Share, Growth, and Forecast 2031 : BAMG Consulting

Lucasbromley — Thu, 09 Jul 2026 03:51:51 +0000

BMAG Consulting Report Reveals Companion Diagnostics Market Poised for Explosive Growth, Set to Reach $16.2 Billion by 2030, Revolutionizing Precision Medicine
FLORIDA, United States, July 5, 2026 — FOR IMMEDIATE RELEASE
BMAG Consulting, a leading global market research and strategic advisory firm, today announced the release of its groundbreaking report, "Companion Diagnostics Market Size, Share & Trends Analysis – By Product, Technology, Indication, End-User, And Segment Forecasts, 2024 – 2030." The comprehensive study projects the global companion diagnostics market to surge from an estimated USD 6.5 Billion in 2023 to a staggering USD 16.2 Billion by 2030, exhibiting an impressive Compound Annual Growth Rate (CAGR) of 14.8% during the forecast period. This significant growth underscores the pivotal role of companion diagnostics (CDx) in advancing personalized healthcare and precision medicine across the globe.
The report highlights that the burgeoning demand for targeted therapies, particularly in oncology, coupled with significant advancements in genomics and molecular diagnostics, are the primary catalysts propelling this market expansion. CDx tests are becoming indispensable tools, enabling healthcare providers to identify patients most likely to respond to specific treatments, thereby optimizing therapeutic outcomes and minimizing adverse drug reactions. BMAG Consulting's analysis offers unparalleled insights into market segmentation, competitive landscape, regulatory dynamics, and emerging opportunities for stakeholders aiming to capitalize on this transformative wave in medical diagnostics.
Download free sample: https://bmagconsulting.com/sample/companion-diagnostics-market
The Regulatory Pivot: Moving Beyond "One-Size-Fits-All" Diagnostics
BMAG Consulting’s report delves into the evolving regulatory landscape, emphasizing a critical shift from broad, "one-size-fits-all" diagnostic approaches to highly specific, biomarker-driven testing. This regulatory evolution is fostering an environment where companion diagnostics are not merely supportive but integral to drug development and approval processes. The increasing collaboration between pharmaceutical companies and diagnostic manufacturers, often mandated by regulatory bodies like the FDA, is accelerating the development and commercialization of new CDx products. The report details how this regulatory pivot is driving innovation, enhancing patient safety, and ensuring more effective resource allocation in healthcare. Furthermore, it explores the complexities and opportunities arising from stringent approval pathways and the growing need for global regulatory harmonization.
Strategic Market Outlook: Demand Engines
The study identifies key demand engines fueling the companion diagnostics market's robust growth. Oncology remains the dominant application segment, driven by the rising incidence of various cancers and the proliferation of targeted cancer therapies. However, significant growth is also anticipated in other therapeutic areas, including neurological disorders, cardiovascular diseases, and infectious diseases, as research uncovers new biomarkers and therapeutic targets. Technological advancements, such as Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), are making CDx tests more accurate, accessible, and comprehensive. The report also sheds light on the increasing adoption of CDx by pharmaceutical & biopharmaceutical companies for drug discovery and development, by reference laboratories for patient testing, and by contract research organizations (CROs) for clinical trials, all contributing to the upward trajectory of the market.
View full report: https://bmagconsulting.com/report/companion-diagnostics-market
About BMAG Consulting:
BMAG Consulting is a global market research and strategic advisory firm renowned for providing actionable insights and in-depth analysis across various industries, including healthcare, life sciences, technology, and manufacturing. Leveraging a team of seasoned analysts and consultants, BMAG Consulting empowers businesses with comprehensive market intelligence, competitive analysis, and strategic recommendations to navigate complex market landscapes, identify growth opportunities, and make informed decisions that drive sustainable success. Our reports are designed to deliver a competitive edge, fostering innovation and strategic positioning for our clients worldwide.
Media Contact:
Mary Joseph,
Senior Consultant,
BMAG Consulting
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

Decentralized Clinical Trials Market Size, Share, Growth, and Forecast 2031 : BAMG Consulting

Lucasbromley — Tue, 07 Jul 2026 10:44:06 +0000

Decentralized Clinical Trials Market Set to Reach $19.6 Billion by 2032, Fuelled by Digital Health Innovation and Patient-Centric Designs, Reports BMAG Consulting
FLORIDA, United States, July 5, 2026 — FOR IMMEDIATE RELEASE
The global pharmaceutical and biotechnology sectors are undergoing a massive paradigm shift, with the Decentralized Clinical Trials (DCT) Market emerging as the cornerstone of modern drug development. According to the latest comprehensive market intelligence report published by BMAG Consulting, the global decentralized clinical trials market size is projected to reach an impressive $19.6 Billion by 2032, registering a robust CAGR of 11.8% during the forecast period.
The report highlights how the integration of telemedicine, wearable devices, digital health technologies (DHTs), and local healthcare providers is redefining patient recruitment, retention, and overall trial efficiency. By shifting the clinical trial landscape from traditional clinical sites directly to patients' homes, life science organizations are experiencing unprecedented reductions in trial timelines and operating costs.
The comprehensive study by BMAG Consulting provides a deep-dive analysis of key market dynamics, technological breakthroughs, competitive benchmarking, and regional growth engines shaping the future of medicine.
Download free sample: https://bmagconsulting.com/sample/decentralized-clinical-trials-market
The Regulatory Pivot: Moving Beyond "One-Size-Fits-All" Diagnostics
As regulatory landscapes evolve globally, regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) are moving decisively away from traditional "one-size-fits-all" clinical trial designs. Regulatory agencies are actively encouraging decentralized methodologies to ensure clinical trials reflect more diverse, real-world patient populations.
Key regulatory developments analyzed in the report include:
Enhanced Diversity Mandates: New guidelines require sponsors to submit Diversity Action Plans, making decentralized and hybrid trials vital for reaching historically underrepresented demographics in rural and remote regions.
Validation of Digital Endpoints: The acceptance of eCOA (electronic Clinical Outcome Assessment) and ePRO (electronic Patient-Reported Outcomes) as primary trial endpoints has cleared the path for fully virtual diagnostic assessments.
Data Security & Privacy Protocols: With the rise of remote data collection, stringent adherence to HIPAA and GDPR is driving innovation in decentralized cybersecurity infrastructure, blockchain-enabled patient registries, and secure cloud storage solutions.

Strategic Market Outlook: Demand Engines
The exponential demand within the decentralized clinical trials market is powered by several critical macroeconomic and technological engines:
The Rise of Personalized Medicine & Complex Biologics: The surge in oncology, rare disease, and gene therapy trials requires specialized, patient-centric monitoring that traditional clinical sites cannot easily facilitate.
Wearable and Remote Monitoring Proliferation: High-fidelity wearables and biosensors allow continuous, real-time data streaming, eliminating the reliance on intermittent, clinical-visit-based patient data.
Cost-Efficiency and Improved Retention: Traditional clinical trials suffer from average patient dropout rates of up to 30%. By removing travel barriers, decentralized models improve patient retention rates to over 90%, significantly driving down the overall cost of drug development.
Strategic Collaborations: Synergies between Contract Research Organizations (CROs), specialized DCT platform providers, and digital health developers are accelerating the deployment of highly scalable hybrid trial designs.

View full report: https://bmagconsulting.com/report/decentralized-clinical-trials-market
About BMAG Consulting
BMAG Consulting is a premier global market research, business intelligence, and strategic consulting firm. We deliver high-impact, data-driven insights to Fortune 500 companies, emerging startups, and institutional investors across the healthcare, biotechnology, life sciences, and technology sectors. Our mission is to empower decision-makers with the foresight, market trends, and competitive intelligence needed to navigate complex industry transformations and accelerate sustainable growth.
Media Contact
Contact Person: Mary Joseph,
Senior Consultant,
Company: BMAG Consulting,
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

AI in Clinical Trials Market Size, Share, Growth, and Forecast 2031 : BAMG Consulting

Lucasbromley — Mon, 06 Jul 2026 08:06:47 +0000

AI in Clinical Trials Market Set to Reach Multi-Billion Dollar Valuation by 2031 as Deep Learning Redefines Drug R&D Pipelines, Reports BMAG Consulting
FLORIDA, United States, July 5, 2026 — FOR IMMEDIATE RELEASE
The global life sciences sector is experiencing an unprecedented technological revolution as artificial intelligence transitions from an experimental tool to the backbone of modern drug development. BMAG Consulting, a global leader in healthcare market intelligence, has released its highly anticipated comprehensive market study, "AI in Clinical Trials Market: Global Forecast and Competitive Analysis."
According to the report, the global AI in Clinical Trials Market is projected to witness exponential growth, capitalizing on the urgent industry demand to reduce skyrocketing drug development costs and accelerate time-to-market. By integrating advanced machine learning (ML), natural language processing (NLP), and predictive analytics, pharmaceutical companies and Contract Research Organizations (CROs) are successfully mitigating high clinical trial failure rates. The research highlights that AI implementation can slash patient enrollment timelines by up to 40%, delivering billions of dollars in structural savings across the drug development lifecycle.
The standard clinical trial model is no longer economically viable. Currently, over 80% of clinical trials face chronic delays due to recruitment bottlenecks, and nearly 90% of drug candidates fail during clinical phases.
BMAG Consulting’s analysis reveals that AI-enabled clinical trial platforms are solving these exact pain points. By scanning vast repositories of Electronic Health Records (EHRs) and real-world data (RWD), AI algorithms match eligible patient cohorts to complex trial protocols in a fraction of the traditional time. Additionally, AI is driving the adoption of Decentralized Clinical Trials (DCTs) by enabling continuous, remote patient monitoring through wearable biosensors and automated data collection tools, drastically reducing patient dropout rates.
Download free sample: https://bmagconsulting.com/sample/ai-in-clinical-trials-market
The Regulatory Pivot: Moving Beyond "One-Size-Fits-All" Diagnostics
Historically, drug development and diagnostic validation followed rigid, monolithic pathways. However, global regulatory bodies—including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—are undergoing a massive regulatory pivot. The industry is moving away from "one-size-fits-all" diagnostic protocols toward dynamic, personalized validation.
AI is the primary catalyst for this shift. By utilizing companion diagnostics (CDx) and digital biomarkers, researchers can pinpoint highly specific patient subpopulations most likely to respond positively to target therapies. Regulatory agencies are actively drafting new frameworks to accommodate AI-generated Synthetic Control Arms (SCAs), which utilize historical patient trial data to replace active control groups. This not only solves ethical dilemmas in rare disease trials but also drastically simplifies the regulatory approval process.
Strategic Market Outlook: Demand Engines
BMAG Consulting identifies three critical demand engines that will dictate the competitive landscape of the AI in clinical trials market over the next decade:
The Rise of Generative AI in Protocol Design: GenAI is being utilized to draft highly optimized trial protocols, predicting potential operational bottlenecks and patient dropout risks before the trial even commences.
Expansion of Oncology and Rare Disease Trials: Due to the complexity of patient targeting in oncology and rare diseases, developers are heavily investing in AI-powered precision medicine tools to identify niche genetic cohorts.
Strategic CRO-Tech Partnerships: Heavyweight CROs are aggressively acquiring or partnering with specialized AI startups to offer end-to-end, AI-native clinical trial management services, reshaping the global market ecosystem.

View full report: https://bmagconsulting.com/report/ai-in-clinical-trials-market
About BMAG Consulting
BMAG Consulting is a premier global market research, advisory, and growth intelligence firm. We specialize in delivering high-impact market studies, feasibility analyses, and strategic consulting services across healthcare, biotechnology, digital health, and emerging technology sectors. Our data-driven insights empower Fortune 500 companies, startups, and institutional investors to navigate disruptive market shifts, identify high-growth opportunities, and execute successful go-to-market strategies.
Media Contact
Mary Joseph, Senior Consultant
BMAG Consulting
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

Dairy Ingredients Market Size, Share, Growth, and Forecast 2030 : BAMG Consulting

Lucasbromley — Fri, 03 Jul 2026 05:52:33 +0000

Dairy Ingredients Market Projected to Reach USD 105.50 Billion by 2030, Driven by Clean-Label Demand and Functional Nutrition Advancements
FLORIDA, United States, June 3, 2026 — FOR IMMEDIATE RELEASE
BMAG Consulting, a global authority in industrial chemistry, food technology, and sustainable agricultural market intelligence, has officially released its 2026 flagship strategic report: “The 2026 Dairy Ingredients Strategic Roadmap: Navigating the Transition to Functional Nutrition, Sustainability-Optimized Processing, and Clean-Label Dairy Solutions.”
The comprehensive study projects the global dairy ingredients market to reach a valuation of USD 105.50 billion by 2030, expanding at a robust CAGR of 5.8% to 6.5% through 2035. This accelerated growth is being catalyzed by a global shift toward high-protein diets, tightening regulatory landscape surrounding food additives, and the urgent requirement for transparent, "Net-Zero" food supply chains.
As the dairy industry faces mounting pressure to enhance nutritional density while ensuring environmental stewardship, dairy ingredients—such as whey proteins, casein, milk powders, and specialized derivatives—have evolved from foundational food components into mission-critical tools for high-value food and beverage, sports nutrition, and medical nutrition systems.
Download free sample: https://bmagconsulting.com/sample/dairy-ingredients-market
The Strategic Pivot: Moving Beyond Conventional Commodity Mandates
In 2026, the dairy ingredients market is undergoing a seismic structural "functional and sustainable" pivot. The market is bifurcated into two primary high-volume tracks: Functional Ingredients (specialized whey proteins, milk protein concentrates, isolates) and Basic Commodities (milk powders, butter derivatives).
According to BMAG Consulting, while bulk ingredients remain the market volume leader by tonnage, high-end functional dairy ingredients are capturing the highest percentage of R&D investment and value-based growth. The implementation of the 2026 "Global Food Traceability Directive" has compelled manufacturers to rapidly integrate advanced processing technologies to improve yield efficiency and ensure compliance with stringent ESG mandates regarding methane footprint and soil-health standards in dairy farming.
Strategic Market Outlook: Demand Engines in Sports Nutrition and Precision Health
A primary growth engine identified in the 2026 report is the rapid expansion of the sports nutrition and lifestyle wellness sectors, which is driving an insatiable requirement for high-purity, fast-absorbing dairy proteins that are compatible with certified clean-label consumer trends.
The Functional Boom: In 2026, the demand for dairy-based peptides and advanced whey hydrolysates has reached an all-time high. Consumers increasingly view dairy ingredients as essential components of proactive health maintenance rather than merely as food staples.
Precision Nutrition: The broader adoption of personalized diets is fostering the use of specific dairy components (such as fractions of caseins or specific whey proteins) as a cornerstone of tailored medical-nutrition solutions, often combined with AI-based health monitoring.
AI-Verified Sourcing and Purity: A burgeoning niche is emerging in "AI-Verified Ingredient Purity," valued at USD 1.20 billion in 2026, as food manufacturing firms seek to provide absolute proof of natural ingredients, quality, and origin through blockchain, smart-contract supply chains, and advanced mass-spectrometry fingerprinting.
Material & Technology Analysis: The Processing Innovation Milestone
2026 is characterized by "Technological Sophistication." The industry is overcoming historical stability and efficacy hurdles through sophisticated processing technologies that ensure ingredient functionality remains potent across diverse application environments, from beverages to baked goods.
Advanced Membrane Filtration: 2026 marks a major technological milestone with the widespread adoption of ultra-fine nanofiltration and cross-flow microfiltration technologies that allow for the isolation of specific protein fractions, enhancing targeted functionality without relying on chemicals.
AI-Driven Formulation Engineering: The R&D sector is utilizing AI-optimized modeling to simulate the texture and taste contribution of new dairy derivatives in food matrices, significantly reducing product development timelines and allowing for "bespoke formulation" tailored to specific mouthfeel and solubility profiles.
Nano-Encapsulation for Nutrient Delivery: The adoption of nano-encapsulation ensures that highly functional, heat-sensitive dairy bioactive compounds—such as lactoferrin or immunoglobulins—are protected from degradation during processing and gastric transit, maximizing the "Effective Window" of health benefits.
View full report: https://bmagconsulting.com/report/dairy-ingredients-market
Regional Dynamics: North America and Europe Lead the Adoption Curve
North America remains the global leader in high-end dairy ingredient adoption in 2026, accounting for over 35% of global value-based demand, anchored by intense investment from major food conglomerates into "Nutrition-Innovation" divisions.
Europe follows as the second-largest market, holding a 30% share, driven by a highly mature food safety framework and intensive societal pressure to reduce agricultural environmental impacts. The European Union’s 2026 regulatory environment provides some of the world’s most robust pathways for certifying sustainable, low-carbon dairy production systems.
Innovation Spotlight: AI-Driven Precision Processing and "Digital Dairy" Twins
2026 is a pivotal year for "Digital Dairy Intelligence." Leading firms are utilizing AI-driven processing plant sensors to create "Digital Dairy" twins, tracking the composition of raw milk in real-time. This allows for site-specific, targeted adjustment of processing parameters—such as temperature optimization and flow control—which decreases energy usage while maximizing the yield, quality, and functionality of the resulting ingredients.
Furthermore, the "Clean-Label Challenge" is being addressed through Natural Texturizers. 2026 has seen the launch of the first commercial-scale "Enzyme-Modified Milk Fractions," which mimic the functionality of traditional stabilizers and additives without the need for synthetic ingredients, ensuring that the food label remains completely clean and natural.
Competitive Landscape
The market is characterized by a strategic "Build-Buy-Partner" trend. Global food and dairy conglomerates are rapidly acquiring specialized biotech laboratories to bolster their "Functional Protein" pipelines. The competitive environment in 2026 is defined by a race toward "Integrated Nutrient Protection," where dairy ingredients are designed in tandem with specific AI-driven product formulation pipelines to offer an "Outcome-Based" solution for human health rather than a purely transactional food commodity.
Recent 2026 developments include the expansion of high-capacity protein fractionation facilities in both North America and Europe to meet the skyrocketing demand for high-efficacy, sustainable dairy ingredient concentrates.
Get a discount on the purchase of this report at: https://bmagconsulting.com/checkout/dairy-ingredients-market
About BMAG Consulting:
BMAG Consulting adopts result-oriented strategies that encompass research of regional as well as international markets, supply chain analysis, data mining, data analysis, identifying industry-specific regulatory and other challenges, opportunities for new product launches, in-depth competitor research and more. We ensure that your business always stays ahead of the curve and gains an edge over competition through the implementation of sustainable growth strategies.
For more information on the 2026 Global Dairy Ingredients Market Reports, visit https://bmagconsulting.com/
Media Contact:
Mary Joseph
Sr Consultant
BMAG Consulting
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

Bioherbicides Market Size, Share, Growth, and Forecast 2030 : BAMG Consulting

Lucasbromley — Tue, 30 Jun 2026 08:26:24 +0000

The global bioherbicides market is valued at USD 2.3 billion in 2024, and is expected to grow to USD 5.5 billion by 2030, exhibiting a remarkable CAGR of 15.5%. This market is experiencing significant growth driven by the growing consumer awareness, government support, and increasing demand for sustainable agricultural practices. Bioherbicides are natural weed control agents derived from living organisms, such as bacteria, fungi, or plant extracts, offering a safer alternative to synthetic herbicides. These products align with the global shift towards eco-friendly farming, particularly in organic agriculture. Rising consumer demand for organic produce, stricter regulations on chemical herbicides, and advancements in biotechnology are among factors driving market growth. The market is poised for robust growth, supported by environmental awareness and technological innovation, though challenges like efficacy and cost remain.
Download free sample: https://bmagconsulting.com/sample/bioherbicides-market
Market Dynamics
Microbial bioherbicides that are crop safe is emerging as a key solution for sustainable and targeted weed control
Microbial bioherbicides sourced from fungi, bacteria, and other microorganisms are becoming a cornerstone of sustainable weed management. These products target specific weeds without harming crops or beneficial organisms. As of August 2021, the EPA reported 18 registered bioherbicides, with nine approved for organic production. Companies like Marrone Bio Innovations (Pro Farm Group) have developed products such as Regalia and Grandevo that demonstrate effective weed and pest control.
The microbial segment is expected to grow rapidly due to its alignment with organic farming and IPM practices. However, challenges include scaling production and ensuring consistent performance across diverse environmental conditions, which companies are addressing through advanced fermentation technologies.
Gene editing and RNAi advancements are propelling the development of next-generation bioherbicides
Advancements in biotechnology are transforming the bioherbicides market by improving product efficacy and targeting capabilities. Innovations like CRISPR gene-editing and RNA interference (RNAi) are enabling the development of bioherbicides with novel modes of action.
In 2024, Harpe Bio partnered with the Broad Institute and Corteva to explore CRISPR technology for herbicide-tolerant crops and bioherbicides. In addition, GreenLight Biosciences announced a breakthrough in May 2025, demonstrating RNA technology’s potential to control hard-to-kill weeds, reducing reliance on synthetic herbicides. These developments address the growing issue of herbicide resistant weeds, affecting over 94 crops globally.
Organic farming expansion supported by company initiatives to become chemical free is another important factor creating global demand for bioherbicides in sustainable agriculture
The global surge in organic farming is a major driver for bioherbicides as they are essential for weed control in chemical-free agriculture. The organic food market is projected to grow at a CAGR of 12% over the next decade, increasing the demand for bioherbicides.
Harpe Bio, for instance, is developing all-natural herbicides suitable for certified organic production, targeting weeds like Palmer amaranth, which can cause up to 91% yield losses in corn. These products support sustainable farming by reducing environmental impact and enhancing crop quality, making them a preferred choice for organic farmers worldwide.
Bioherbicides face challenges in efficacy & cost effectiveness when compared to synthetic herbicides
Despite their benefits, bioherbicides face challenges in matching the efficacy and cost-effectiveness of synthetic herbicides. Bioherbicides require precise application and are sensitive to environmental conditions, which can limit their performance. Production costs are also higher due to complex processes like microbial fermentation. For example, large-scale production facilities for microbial bioherbicides are limited, particularly in developing regions. Companies like Emery Oleochemicals are addressing these challenges by developing cost-effective plant extract-based formulations, while ongoing research aims to improve efficacy through advanced biotechnologies.
Key Market Players
Key market players operating in the Bioherbicides market include Marrone Bio Innovations Inc. (Pro Farm Group) Davis (U.S), Emery Oleochemicals (U.S), Harpe Bio Raleigh (U.S), Syngenta Basel (Switzerland), Verdesian Life Sciences (U.S), Special Biochem Pvt. Ltd (India), Seipasa (Spain), Bayer (Germany), Certis (U.S), Agrilife (India), EcoPesticides (U.S), BASF (Germany), Mycologic (U.S), and Hindustan Biotech (India). Leading companies are driving innovation in bioherbicides market to meet sustainability demands through strategic partnerships and advanced technologies. These include investing in microbial-based solutions, testing drone-applied bioherbicides for precision farming, and developing cost-effective organic herbicides for small farmers. Start-ups are also entering the space with AI-driven weed detection and longer-lasting formulations, accelerating the shift toward eco-friendly weed control.
View full report: https://bmagconsulting.com/report/bioherbicides-market
Segmentation
This research report categorizes the global bioherbicides market based on type, form, application, and region.
By Type
Microbial
Biochemical
Others
By Form
Granular
Liquid
Powder
By Application
Agricultural Crops
Fruits & Vegetables
Flowers & Ornamentals
Others
By Region
North America
South America
Europe
APAC
Middle East and Africa
Recent Developments
In July 2022, Marrone Bio Innovations was acquired by Bioceres Crop Solutions, which led to the formation of Pro Farm Group. This merger created a global leader in sustainable agricultural solutions, combining Marrone’s biopesticide expertise with Bioceres’ crop productivity focus.
In April 2023, Harpe Bio secured a USD 10.5 million investment round led by ADM, with contributions from iSelect Fund Management and Alexandria Investment Ventures. This funding supports the development of natural herbicide formulations and herbicide tolerant crop systems. Harpe Bio also partnered with the Broad Institute and Corteva to develop bioherbicides using CRISPR technology.
In May 2025, GreenLight Biosciences announced a breakthrough in its bioherbicide pipeline, using RNA technology to control hard-to-kill weeds. This development offers a sustainable alternative to synthetic herbicides, reducing environmental impact.
BASF introduced LibertyLink and Liberty ULTRA herbicides, which offer weed control options for glufosinate-tolerant crops like soybean. These herbicides, powered by Glu-L technology, is a post-emergence herbicide for broad-spectrum weed control in glufosinate-tolerant crops, including soybean.
For more information on the 2026 Global Bioherbicides Market Reports, visit https://bmagconsulting.com/
Media Contact:
Mary Joseph
Sr Consultant
BMAG Consulting
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

Energy Storage Chemicals Market Size, Share, Growth, and Forecast 2030 : BAMG Consulting

Lucasbromley — Thu, 25 Jun 2026 02:52:48 +0000

The energy storage chemicals market was valued at USD 112.2 billion in 2025, and is expected to reach USD 125.4 billion by 2030, recording a CAGR of 17.0%. There is a rise in energy storage chemicals because globally the energy system is changing from fossil fuels to renewables, and renewable sources like solar and wind are intermittent by their nature. Therefore, to make this transition reliable, energy must be stored efficiently, safely, and on a large scale, in which the demand for battery electrolytes, electrode materials, redox chemicals, and such thermal storage materials and hydrogen-related chemicals is expected to grow. On the other hand, rapid growth in electric vehicles, consumer electronics, and data centers keeps boosting battery production volumes, thereby multiplying chemical consumption across the value chain.

Download free sample: https://bmagconsulting.com/sample/energy-storage-chemicals-market

Market Dynamics
Rising Intermittency from Solar & Wind Generation
The rapid scale-up of solar and wind energy is key structural drivers for the energy storage chemicals market because these sources are intermittent and non-dispatchable. Moreover, the growing penetration of renewables increases the likelihood of mismatches between generation and load on the grid, hence the critical need for energy buffering, time-shifting and grid-stabilizing solutions. Chemical-based storage systems (batteries, flow batteries, and thermal storage) allow saving of excess renewable power until a period of generation drop and consequently increased demand for electrolytes, redox materials, and other specialty chemicals.
On the place of renewables moving from pilot deployment to system level integration, storage becomes not a supporting technology but a core grid asset. Fast-response storages for frequency regulation, reserve capacity, and reliability become more common in utility operations, redirecting investment from conventional peaking plants toward storage-enabled grid. Not only does this play out in scaling chemical volumes, but also in setting subsequently more stringent performance requirements that will drive innovation toward advanced, safer, and longer-life energy storage chemistries.

High Cost and Price Sensitivity of Advanced Storage Chemistries
The high costs and price sensitivity remain major restraining factors because energy storage, especially from grid scale to renewable-linked applications, is fundamentally dictated by Levelized Cost of Storage (LCOS) rather than the sophistication of the technology. Advanced storage chemistries must depend upon high-purity specialty chemicals, complicated synthesis routes, limited supplier bases, and low manufacturing scale, all of which continue to keep the material costs high. So, even if these chemistries are more advanced to start with, it will only be hard to grab attention unless they can show clear short-term advantages with respect to costs over those that already exist.

On the demand side, utilities and infrastructure developers work under shackles of tight capex and payback constraints, making them highly sensitive to small increments in chemical input costs. At the same time, constant price depressions in mature chemistries, like lithium-ion, set an increasingly aggressive benchmark by forcing new storage chemistries to compete against declining cost curves. Until there is improvement in scale and manufacturing efficiency, the high costs will remain a major hindrance to actual universal acceptance.

By product type, lithium-based chemical products is expected to be the fastest growing during the forecast period. This is due to the current industry standard for battery technologies including lithium and a compelling combination of demand pull, scale economies, and technology lock-in. Lithium-ion systems offer a commercially proven balance of energy density, efficiency, life cycles, and response speed. Therefore, lithium-ion systems have become the default for electric vehicles, grid-scale storage, consumer electronics, and projects involving renewable integration. With increasing scaling of final markets, there is growth in terms of volume experienced by lithium salts, electrolytes, cathode and anode materials, binders, and additives in direct and disproportionate proportions.

Asia-Pacific has the largest market share in energy storage chemicals. This control is largely attributed to the region's end-to-end control of the battery value chain, from raw material processing and chemical refining to battery manufacturing and large-scale deployment. Asia Pacific has the world's highest concentration of lithium-based producers for chemicals and electrolytes, as well as cathode/anode material suppliers, all closely tied to the downstream battery gigafactories. Due to rapid growth in electric vehicles, renewable energy installations, and grid-scale energy storage projects, the Asia Pacific region accounts for the largest share of global demand.

Key Market Players
Key players active in the energy storage chemicals market include BASF SE (Germany), Albemarle Corporation (USA), LG Chem (South Korea), Panasonic (Japan), 3M (USA), Cuberg (USA), Siemens (Germany), Danfoss (Denmark), Linde AG (Ireland), Abengoa Solar (Spain), Duracell, Inc. (USA), Exide Technologies (France), General Electric (USA), and Hitachi Energy Global (Switzerland).

View full report: https://bmagconsulting.com/report/energy-storage-chemicals-market

Segmentation
This research report categorizes the energy storage chemicals market based on product type, battery technology, application, and region.
By Product Type
Lithium-Based Chemicals
Nickel-Based Chemicals
Cobalt Chemicals
Graphite & Carbon Materials
By Battery Technology
Lithium-ion Batteries
Lead Acid Batteries
Flow Batteries
Sodium ion Batteries
By Application
Electric Vehicles
Consumer Electronics
Industrial & Commercial Energy Storage System
Utility & Grid Storage
By Region
North America
Latin America
Europe
APAC
Middle East and Africa

Recent Developments
August 2025- SGS launched the first Al-powered automated system for thermal runaway testing designed for energy storage batteries. The solution was developed with Chongqing Energy College (CEC) to help with fire safety concerns with the fast global growth of battery energy storage systems (BESS) at commercial, industrial, and residential levels.

July 2025- Echogen Power Systems shared that its strategic partner, Westinghouse Electric Company, officially signed a MoU (Memorandum of Understanding) with Vodohospodárska Výstavba (VVB). Together, they are gearing up toward the development of Europe's very first grid-scale Pumped Thermal Energy Storage (PTES) system in Slovakia.

April 2025- MGA Thermal Pty Ltd declared the completion of the world's first industrial steam-heat energy storage demonstration project. The demonstration project, operated by MGA Thermal's ETES, stored 5 MWh of energy at a rated thermal power dispatch of 500 kW, delivering continuous thermal superheated steam for 24 hours.

January 2022- Voith GmbH & Co, KGaA acquired a controlling interest in Green Highland Renewables. The acquisition aimed to broaden Voith's involvement in maintaining, operating, and advancing hydropower facilities, enhancing its industry presence.

May 2022- Toshiba Corporation launched the 125 VDC SCiB ESS, which combines the dependence of LTO battery chemistry with expandable and flexible cabinet. It is made suitable for integration with DC Load applications or Uninterruptible Power Systems (UPS) applications.

Related Reports
Explore Smart Textiles Market
Explore Aerosol Disinfectants Market
Explore Polylactic Acid (PLA) Market

Buy Now : https://bmagconsulting.com/checkout/energy-storage-chemicals-market
For more information on the 2026 Global Energy Storage Chemicals Market Reports, visit https://bmagconsulting.com/

Media Contact:
Mary Joseph
Sr Consultant
BMAG Consulting
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/

Dairy Ingredients Market Size, Share, Growth, and Forecast 2030 : BAMG Consulting

Lucasbromley — Mon, 22 Jun 2026 08:56:37 +0000

Dairy ingredients are processed components derived from milk that provide nutritional and health benefits. These ingredients enhance flavor, texture, stability, and shelf life of a wide range of products, including bakery items, infant formulas, and nutritional supplements. This market is growing due to shifting consumer preferences toward high-protein diets and nutritional supplements, driven by health awareness and fitness trends. Increasing demand for ready-to-eat foods and naturally sourced ingredients is further fueling market growth. With a growing population, the demand for milk and dairy ingredients is rising, but supply shortages create challenges for processing industries. This gap has led to increased adulteration in dairy ingredients, affecting quality and safety, as companies struggle to meet market demands. In Europe and North America, the dairy market thrives due to stringent quality standards, advanced processing technologies, and innovative product developments. Europe's rich dairy farming tradition and strong R&D infrastructure fuel growth, with rising demand for specialized ingredients, especially in functional foods and sports nutrition. The APAC region is steadily gaining traction in the dairy market, driven by urbanization, rising incomes, and demand for innovation.

Market Dynamics
Growing Health Consciousness is Driving Innovations in the Dairy Products and Ingredients Markets
Consumers are increasingly prioritizing health without sacrificing taste, leading to the creation of dairy products that cater to both indulgence as well as wellness. Low-fat ice creams, sugar-free options, and probiotic-rich frozen yogurt are examples of this shift. These products reflect a growing consumer preference for healthier food choices and better nutrition. Manufacturers are responding to these demands by developing dairy products that not only taste great, but also offer health benefits, such as probiotics for digestive health or reduced sugar for calorie-conscious consumers. This trend is reshaping the dairy industry, pushing companies to innovate and meet evolving consumer expectations.

Download free sample: https://bmagconsulting.com/sample/dairy-ingredients-market

Technological Advancements Enhancing Dairy Production Efficiency and Ingredients Business
The dairy industry is leveraging advanced technologies like AI, robotics, and smart sensors to revolutionize production processes. These innovations help reduce milk wastage, monitor cattle health, and optimize logistics. Automated milking systems and IoT integration are enhancing operational efficiency, improving milk quality, and increasing safety. By digitalizing operations, producers can optimize production schedules, predict maintenance needs, and ensure product consistency. This automation leads to lower production costs and less human error. Additionally, AI-driven analytics are improving supply chain management by forecasting demand, optimizing inventory, and reducing waste. These technological advancements are driving the dairy industries and further dairy ingredients processing by improving both the production process and product quality.
Powdered Dairy Ingredients Dominate the Market Due To Longer Shelf Life, Ease Of Storage, And Versatility In Food Applications
Dairy ingredients are available in both powdered and liquid forms, each serving distinct roles in the food industry. Liquid forms, such as unpasteurized farm milk, skimmed milk, fresh cream, etc., are often used directly in the production of cheese, butter and other dairy processes. These liquids may be further concentrated or processed to create specialized products.

In contrast, powdered dairy ingredients, including milk powder, whey, and buttermilk, offer a longer shelf life, making them ideal for storage, transportation, and use in food formulations such as beverages, baking, and dairy products. Moreover, powdered dairy ingredients retain nutritional benefits while providing convenience, flexibility, and cost-effectiveness in various applications.
Adulteration of Dairy Ingredients Is A Major Global Challenge Due To Lack Of Policies To Prevent The Trade Of Adulterants
Adulteration in dairy ingredients remains a significant global challenge, especially due to the lack of strict monitoring and enforcement of policies. A major concern is the adulteration of raw materials, such as milk, which adversely affects the quality of products like milk powder, cheese, and butter. The introduction of harmful additives and lower-quality substances to meet market demand & reduce costs has been known to compromise product safety and quality. As a result, consumers are likely to face serious health risks, including digestive issues and food poisoning. To mitigate these risks, stricter regulations and improved supply chain transparency are essential to ensure the purity and authenticity of dairy ingredients.

View full report: https://bmagconsulting.com/report/dairy-ingredients-market

Key Market Players
Key market players functioning in the dairy ingredients market include Arla Foods (Denmark), Friesland Campina (The Netherlands), Dairy Farmers of America (US), Glanbia (Ireland), Ingredia SA (France), Saputo (Canada), Kerry Group (Ireland), AMCO Proteins (US), Hoogwegt Group (The Netherlands), Batory Foods (US), Fonterra Co-operative Group (New Zealand), Ornua (Ireland), Prolactal (Austria), Groupe Lactalis (France), Valio (Finland), Agropur (Canada), and Euroserum (France), among others. Companies in the dairy ingredients business are focusing on producing protein-rich dairy products, dairy products with added health benefits, and infant nutrition. Advancements in dairy processing technology, sustainable sourcing, and product innovations are also some of the critical factors driving the market.

Segmentation
This research report categorizes the global dairy ingredients market based on type, application, form, and region.
By Type
Milk Powders
Whey Ingredients
Milk Protein Concentrates
Casein & Derivatives
Lactose & Derivatives
Others
By Application
Bakery & Confectionery
Dairy Products
Infant Nutrition
Sports Nutrition
Pharmaceuticals
By Form
Powder
Liquid
By Region
North America
South America
Europe
APAC
Middle East and Africa

Recent Developments
In 2022, Arla invested EUR 190 million in expanding its Pronsfeld dairy in Germany to boost milk powder production. The new facility includes a 51-meter-high drying tower, processing 685 million kilos of milk annually. This expansion supports Arla's growing international demand for affordable, sustainable dairy products.
In 2022, Fonterra's new online platform, myNZMP, simplified the purchase of dairy ingredients such as milk powder and specialty proteins. It was created in response to customer demands for improved convenience, flexibility, and access to more detailed product information, thus offering easier ordering and greater customer satisfaction.
In May 2024, Epi Ingredients introduced an additive-free butter powder, a clean-label solution for manufacturers. This product, made from natural milk fat, is ideal for applications in pastry, baked goods, sauces, and dairy products. It offers easy incorporation, good hydration, and ease of storage, meeting the consumer demand for clean-label ingredients.
Lactalis Ingredients inaugurated a new whey drying tower at its Verdun factory in France in November 2021. The tower enhanced production by 30,000 tonnes of whey powder annually under the Flowhey brand. It incorporates advanced drying technology to optimize efficiency, reduce environmental impact, as well as to expand Lactalis' international market presence.

About BMAG Consulting:
BMAG Consulting adopts result-oriented strategies that encompass research of regional as well as international markets, supply chain analysis, data mining, data analysis, identifying industry-specific regulatory and other challenges, opportunities for new product launches, in-depth competitor research and more. We ensure that your business always stays ahead of the curve and gains an edge over competition through the implementation of sustainable growth strategies.
For more information on the 2026 Global Dairy Ingredients Market Reports, visit https://bmagconsulting.com/

Media Contact:
Mary Joseph
Sr Consultant
BMAG Consulting
Email: Mary.Joseph@bmagconsulting.com
Website: https://bmagconsulting.com/